Cargando…
In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis
Background: The novel echinocandin CD101 has stability properties amenable to topical formulation for use in the treatment of acute vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC). CD101 has demonstrated potent antifungal activity at pH 7, but assessment of its activity at the physiological...
Autores principales: | Boikov, Dina A., Locke, Jeffrey B., James, Kenneth D., Bartizal, Ken, Sobel, Jack D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400080/ https://www.ncbi.nlm.nih.gov/pubmed/28158577 http://dx.doi.org/10.1093/jac/dkx008 |
Ejemplares similares
-
Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species
por: Locke, Jeffrey B., et al.
Publicado: (2016) -
CD101: a novel long‐acting echinocandin
por: Zhao, Yanan, et al.
Publicado: (2016) -
Analysis of molecular resistance to azole and echinocandin in Candida species in patients with vulvovaginal candidiasis
por: Lotfali, Ensieh, et al.
Publicado: (2022) -
Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
por: Ong, Voon, et al.
Publicado: (2016) -
In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)